TAK241220C15000
- 0.04
- -0.01-20.00%
Takeda Pharmaceutical Newsroom
Alloy Therapeutics Signs Collaboration And License Agreement With Takeda To Develop Takeda's Proprietary Induced Pluripotent Stem Cell Derived CAR-T Cell Platform And IPSC-Derived CAR-NK Platform
Express News | Alloy: Establishing a Japanese Unit in Kanagawa Prefecture
Express News | Alloy: Gains Co-Exclusive Rights to Commercialize Icar-T and Icar-Nk Products for Oncology Indications
Express News | Alloy Therapeutics Signs Collaboration and License Agreement With Takeda to Develop Cell Therapy Platform
TD Cowen Maintains Takeda Pharmaceutical(TAK.US) With Buy Rating, Announces Target Price $16
Analysts Offer Insights on Healthcare Companies: Lineage Therap (LCTX), Veeva Systems (VEEV) and Takeda Pharmaceutical Company (TAK)
Chordia Research Memo (2): Spin-off from takeda pharmaceuticals sp adr, focusing on the development of anti-cancer drugs.
■Company Overview of Chordia Therapeutics＜190A＞. 1. Company History The company was founded in October 2017 as a biotech venture by six drug discovery researchers who had been developing anti-cancer drugs of low molecular compounds at Takeda Pharmaceuticals. They selected four candidates from the pipeline that had been developed during their time at Takeda Pharmaceuticals and entered into an exclusive global license agreement for research, development, manufacturing, and sales with Takeda Pharmaceuticals in November of the same year.
Chordia---bioventure advancing the development of potential blockbuster anticancer drugs at block inc.
Chordia Therapeutics <190A> is a biotech venture founded by drug discovery researchers spun out from Takeda Pharmaceutical Co., Ltd. <4502>, specializing in the development of small molecule anticancer drugs. They consider core business from exploratory research to clinical research, and domestically, they handle manufacturing and sales through partnership strategies, aiming for early monetization by licensing out overseas. They went public on the Tokyo Stock Exchange Growth Market in June 2024.
Global Companies With at Least 50% U.S. Revenue Exposure as Trump Eyes Tariffs: BofA
US Manufacturing Index Rises To 43, Highest Since 2020
AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients
The PRIDE indicators include achieving Gold for four consecutive years in 2024, as well as receiving the first Rainbow certification.
On November 15, 2024, the PRIDE indicators will recognize for the fourth consecutive year the acquisition of PRIDE Gold, as well as the first-ever Rainbow certification, which evaluates corporate initiatives towards LGBTQ+ communities. This includes top recognition in the PRIDE indicators for efforts promoting collaboration across sectors. The recognition reflects Takeda's commitment to diversity, equity & inclusion based on our corporate philosophy.
Urgency, Debate Mark COP29 As Leaders Push For Carbon Market Rules, Worry About Trump
List of cloud breakout stocks (Part 1) [Ichimoku Kinko Hyo Cloud Breakout Stock List]
○List of breakout stocks in the market Code Stock Name Closing Price Leading Span A Leading Span B Tokyo Stock Exchange Prime ＜1808＞ Haseko 1882 1877.25 1754 ＜1861＞ Kumagai Gumi 3600 3583.75 3365 ＜1884＞ Nichidoro 1715 1708.25 1600 ＜1925＞ Daiwa House 4627 4564.54 158.5 ＜1942＞ Kandenko 2285 2196.25
ADR Japan stock ranking ~ Yucho Bank and others are generally selling more, Chicago is 365 yen cheaper than Osaka at 39,135 yen ~
Japanese stocks of American Depositary Receipts (ADRs) such as Yucho Bank <7182>, Hitachi Ltd sponsored ADR <6501>, Toyoda Automatic Loom Works <6201>, Renesas <6723>, Tokyo Electron <8035>, Toyota Motor <7203>, Honda Motor <7267>, etc., declined compared to the Tokyo Stock Exchange (converted at 152.58 yen per dollar), leading to overall selling pressure. The Chicago Nikkei 225 Futures settlement price was 365 yen lower at 39,135 yen compared to Osaka daytime trading. The US stock market is rising. The Dow Jones Industrial Average is up 259.65 dollars.
Application for partial change approval in Japan for the combination therapy of Vectibix intravenous drip and Lumakras tablets for unresectable advanced or recurrent colorectal cancer with KRAS G12C mutation.
On November 8, 2024, our company today filed for partial changes in manufacturing and marketing approval in japan for use of a combination therapy of Vectibix intravenous drip and Lumakras tablets in the treatment of KRAS G12C mutation-positive unresectable advanced recurrent colorectal cancer. Vectibix intravenous drip (generic name: panitumumab (recombinant DNA), hereinafter referred to as "Vectibix") for KRAS G12C mutation-positive unresectable advanced recurrent colorectal cancer.
Takeda (TAK.US) has initiated two Phase 3 clinical trials in china, launching innovative therapies for the disease of "excessive sleep".
TAK-861 is an oral orexin receptor 2 (OX2R) agonist. The product has been previously included in the breakthrough therapy category for the treatment of type 1 narcolepsy (NT1) by the China NMPA, as well as receiving breakthrough therapy designation from the FDA in the usa for the excessive daytime sleepiness associated with NT1.
Nikkei Stock Average Contribution Ranking (pre-closing) - The Nikkei average continued to rise significantly, with Advantest pushing up about 155 yen per share alone.
The number of rising stocks in the Nikkei average constituent stocks at the closing six days ago was 206 stocks up, 18 stocks down, and 1 stock unchanged. The Nikkei average continued to rise significantly. It closed the morning session at 39,341.44 yen, up 866.54 yen (+2.25%) from the previous day, with an estimated volume of 1,040 million shares traded. The U.S. market on the 5th day was up. The Dow Jones Average closed at 42,221.88 yen, up 427.28 yen, and the Nasdaq closed at 18,439.17, up 259.19 points. Through the presidential election.
Alkermes Raised to Buy by Stifel on Increased Confidence for ALKS2680
List of Conversion Stocks (Part 1) [List of Parabolic Signal Conversion Stocks]
○ List of buy converted stocks in the market Code Stock name End price SAR TSE main board ＜1332＞ Nissui 938 886 ＜1605＞ INPEX 2009 1916 ＜1939＞ Yondenko 1360 1209 ＜1941＞ Chudenko 3385 3130 ＜1976＞ Myojo Kogyo 1319 1260 ＜1980＞ DaiDan 3020 2831 ＜2060＞ Feed One 8428 10 ＜2124＞ J